Nutranomics, Inc. (NNRX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNutranomics, Inc. (NNRX) trades at $0.00005. Nutranomics, Inc. focuses on researching, developing, and selling nutritional food products and supplements. The company distributes its products through sales representatives and retail stores across North America and Asia. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for NNRX: NNRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Nutranomics, Inc. (NNRX) Healthcare & Pipeline Overview
Nutranomics, Inc., founded in 1995, operates in the nutritional supplement market, offering a range of products including vitamin, mineral, and herbal supplements. The company distinguishes itself through its Nutritional Blood Analysis tool and patented Assimilation Enhancing System, distributing products via sales representatives and retail channels in North America and Asia.
What Is the Investment Thesis for NNRX?
Nutranomics, Inc. presents a challenging investment case given its negative profit and gross margins of -232.9% and -108.0%, respectively. The company's small market capitalization and OTC listing introduce liquidity and regulatory risks. A potential growth catalyst lies in expanding its distribution network in Asia and North America. The company's proprietary Nutritional Blood Analysis tool and Assimilation Enhancing System could offer a competitive edge if effectively marketed. However, the company's financial performance and OTC status require careful consideration.
Based on FMP financials and quantitative analysis
NNRX Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- P/E ratio of -0.07 suggests the company is not currently profitable.
- Profit margin of -232.9% reflects significant losses relative to revenue.
- Gross margin of -108.0% indicates that the cost of goods sold exceeds revenue.
- Beta of -0.06 suggests the stock price is less volatile than the overall market.
Who Are NNRX's Competitors?
NNRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NNRX's Key Strengths?
Proprietary Nutritional Blood Analysis tool.
- Patented Assimilation Enhancing System.
- Established distribution network in North America and Asia.
- Wide range of nutritional supplements (approximately 480 products).
What Are NNRX's Weaknesses?
Negative profit and gross margins.
- Small market capitalization.
- Limited financial resources.
- OTC listing introduces liquidity and regulatory risks.
What Are the Key Risks for NNRX?
Financial-distress signal — its Altman Z-Score of -2.52 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition in the dietary supplements industry.
- Evolving regulatory landscape and compliance requirements.
- Changing consumer preferences and trends.
- Product liability claims.
- Negative profit and gross margins.
What Are NNRX's Competitive Advantages?
- Patented Assimilation Enhancing System provides a unique selling proposition.
- Nutritional Blood Analysis tool offers a differentiated customer experience.
- Established distribution network in North America and Asia.
- Long-standing presence in the nutritional supplement market (founded in 1995).
What Does NNRX Do?
Nutranomics, Inc., established in 1995, is a healthcare company focused on the research, development, and sale of nutritional food products. The company offers a diverse portfolio of approximately 480 nutritional supplements, encompassing vitamin, mineral, herbal, and probiotic formulations. A key differentiator for Nutranomics is its proprietary Nutritional Blood Analysis, a real-time video monitoring tool used to examine a customer's blood cells. Complementing this is the patented Assimilation Enhancing System, designed to improve nutrient absorption. Beyond product offerings, Nutranomics provides educational services, including various analyses, training programs, certifications, and group presentations catering to both individuals and industry professionals. The company utilizes a distribution network comprising sales representatives throughout North America and Asia, alongside retail store partnerships. Nutranomics also maintains a strategic partnership with Terra-Formance, LLC. Headquartered in Salt Lake City, Utah, Nutranomics continues to operate in the competitive nutritional supplement market.
What Products and Services Does NNRX Offer?
- Researches and develops nutritional food products.
- Formulates and sells approximately 480 nutritional supplements.
- Offers vitamin, mineral, herbal, and probiotic supplements.
- Provides Nutritional Blood Analysis using real-time video monitoring.
- Offers the patented Assimilation Enhancing System to improve nutrient absorption.
- Provides educational services, including analyses, trainings, and certifications.
- Distributes products through sales representatives in North America and Asia.
- Sells products through retail stores.
How Does NNRX Make Money?
- Sells nutritional supplements directly to consumers through sales representatives.
- Generates revenue through retail partnerships and distribution agreements.
- Offers educational services and training programs for additional income.
- Licenses its patented Assimilation Enhancing System.
What Industry Does NNRX Operate In?
Nutranomics, Inc. operates within the competitive dietary supplements industry. This industry is characterized by increasing consumer interest in health and wellness, driving demand for vitamins, minerals, and herbal supplements. However, the market is also highly fragmented, with numerous players ranging from large multinational corporations to smaller, niche-focused companies. Regulatory scrutiny and evolving consumer preferences pose ongoing challenges. Competitors like ACUR, AXRX, ENDV, FLHLF, and MEDD also operate in this space, creating a crowded market.
Who Are NNRX's Key Customers?
- Health-conscious individuals seeking nutritional supplements.
- Retail stores and distributors in North America and Asia.
- Healthcare professionals and wellness centers.
- Individuals seeking educational services related to nutrition.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Nutranomics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Jonathan Bishop. NNRX has traded publicly since 2013.
Key Financial Metrics
Return on equity for Nutranomics, Inc. stands at 99.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.8%, showing how much profit it generates from its asset base. A current ratio of 0.18 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Nutranomics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.52 places it in the distress zone, a signal of elevated financial risk.
NNRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
NNRX Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
NNRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NNRX.
Price Targets
Wall Street price target analysis for NNRX.
NNRX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NNRX; grades run from A+ (80-100) to F (below 30).
Leadership: Jonathan Bishop
CEO
Jonathan Bishop is the CEO of Nutranomics, Inc. His background includes experience in managing small teams and overseeing the operations of the company. He is responsible for the strategic direction and overall performance of Nutranomics, Inc., which currently employs one individual.
Track Record: Under Jonathan Bishop's leadership, Nutranomics, Inc. has continued to offer a range of nutritional supplements and related services. Specific milestones and achievements during his tenure are not detailed in the provided information. His focus remains on maintaining the company's existing product lines and distribution channels.
NNRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nutranomics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer listing requirements, resulting in increased risk for investors.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume on the OTC Other market.
- Lack of transparency regarding financial reporting and disclosure.
- Potential for price manipulation and fraud.
- Higher risk of delisting or trading suspension.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Determine the company's ownership structure and potential conflicts of interest.
- Check for any history of fraud or regulatory violations.
- Consult with a qualified financial advisor before investing.
- Long-standing presence in the nutritional supplement market (founded in 1995).
- Proprietary Nutritional Blood Analysis tool.
- Patented Assimilation Enhancing System.
- Distribution network in North America and Asia.
NNRX Healthcare Stock FAQ
What are the main risks for NNRX?
The main risks for Nutranomics, Inc. include its negative profit and gross margins, small market capitalization, and OTC listing. The company faces intense competition in the dietary supplements industry and must navigate an evolving regulatory landscape.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market investments carry significant risks.